Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder

Summary

This is an open-label pilot study of up to 1200 mg/day of carbamazepine ER (Equetro) in the treatment of children who meet DSM-IV criteria for Bipolar I, Bipolar II, or Bipolar Spectrum Disorder. The main goal of this study is to begin to address the void of information on safety, tolerability and effectiveness of Equetro in the treatment of Pediatric Bipolar Disorder.

Timeline

Start

2005-07

Primary completion

2007-08

Completion

—

Drugs

Indications